首页|期刊导航|中华医学杂志（英文版）|Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer
Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer
ZHUO Ming-lei DUAN Jian-chun WANG Yu-yan GUO Qing-zhi LIU Xu-yi LIU Ning-hong WANG Jie WU Mei-na ZHAO Jun Sonya Wei Song BAI Hua WANG Shu-hang YANG Lu AN Tong-tong WANG Xin
中华医学杂志（英文版）2011，Vol.124Issue(21)：3510-3514,5.
中华医学杂志（英文版）2011，Vol.124Issue(21)：3510-3514,5.DOI:10.3760/cma.j.issn.0366-6999.2011.21.014
Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer
Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer
摘要
Abstract
Background The genotype of epidermal growth factor receptor (EGFR) is associated with tyrosine kinase inhibitor and effectiveness of therapy,but its role in cytotoxic chemotherapy is still unknown.Previous studies indicated that certain EGFR mutations were associated with response and progression free survival following platinum based chemotherapy.Our recent studies have identified that EGFR genotypes in the tumour tissues were not associated with response to the first-line chemotherapy in Chinese patients with advanced non-small cell lung cancer (NSCLC).In this study,we investigated associations of EGFR genotypes from plasma of patients with advanced NSCLC and response to first-line chemotherapy and prognosis.Methods We enrolled 145 advanced NSCLC patients who had received first-line chemotherapy in our department.We examined plasma EGFR genotypes for these patients and associations of EGFR mutations with response to chemotherapy and clinical outcomes.Results There were 54 patients with known EGFR mutations and 91 cases of wild types.No significant difference was detected in the response rate to first-line chemotherapy between mutation carriers and wild-type patients (37.0％ vs.31.9％).The median survival time and 1-,2-year survival rates were higher in mutation carriers than wild-types (24months vs.18 months,85.7％ vs.65.7％ and 43.7％ vs.25.9％,P=0.047).Clinical stage (IV vs.Ⅲb),response to the first-line chemotherapy (partial vs.no) and EGFR genotype were independent prognostic factors.Conclusion Plasma EGFR mutations in the Chinese patients with advanced NSCLC is not a predictor for the response to first-line chemotherapy,but an independent prognostic factor indicating longer survival.关键词
non-small cell lung cancer/plasma/epidermal growth factor receptor mutation/first line chemotherapy/prognosis/targeted therapy/gefitinibKey words
non-small cell lung cancer/plasma/epidermal growth factor receptor mutation/first line chemotherapy/prognosis/targeted therapy/gefitinib引用本文复制引用
ZHUO Ming-lei,DUAN Jian-chun,WANG Yu-yan,GUO Qing-zhi,LIU Xu-yi,LIU Ning-hong,WANG Jie,WU Mei-na,ZHAO Jun,Sonya Wei Song,BAI Hua,WANG Shu-hang,YANG Lu,AN Tong-tong,WANG Xin..Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer[J].中华医学杂志（英文版）,2011,124(21):3510-3514,5.基金项目
The study was supported by grants from the National High Technology Research and Development Program of China (“863”Program,No.2006AA02A401),the Capital Development Foundation (No.30772472),and Peking University 985 Program (No.2-013-39). （“863”Program,No.2006AA02A401）
